Little River Memorial Hospice Medicare Approved Location: 450 West Locke Street, Suite B, Ashdown, Arkansas 71822 Phone: (870) 898-4105 |
News Archive
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
By offering family planning services to people seeking HIV/AIDS information and treatment, Africa's population growth rate could be curbed by 2.5 percent, health experts said Monday during an international family health conference in Kampala, Uganda, Agence France-Presse reports (11/16).
Just three types of simple self-reported health measures can predict which Medicaid-eligible adults are more likely to access intensive and costly health services over the next year, a new study in Health Services Research suggests. The findings could provide a new way to save a substantial amount of money while also providing better care for Medicaid's neediest patients.
Brent Christner, LSU professor of biological sciences, in partnership with colleagues in Montana and France, recently found evidence that rain-making bacteria are widely distributed in the atmosphere.
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine. The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).
› Verified 6 days ago